Bio-Matrix Scientific Group Inc.'s Regen BioPharma Acquires Cancer Vaccine Technology With Initial Focus on Breast Cancer
SAN DIEGO, CA--(Marketwired - May 06, 2013) - Regen BioPharma, wholly owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), announced today it has purchased patent #8,389,708 from Professor Wei-Ping Min of the University of Western Ontario, London, Canada. This patent covers a novel means of stimulating the immune system against cancer through blockade of a cancer specific molecular pathway (gene silencing). Preclinical studies demonstrating effective stimulation of anticancer immunity and molecular mechanisms mediating therapeutic effects of the technology have been reported in the Journal of Immunology(1).
"The blockbuster potential of cancer immune therapies is illustrated by the $1.66 Billion sales of Herceptin(2), a monoclonal antibody used to treat breast cancer, in 2011," said David Koos, Chairman and CEO of Bio-Matrix Scientific Group Inc. and its subsidiary, Regen BioPharma Inc. "This newly acquired technology has passed the preclinical stages of testing and we are eager to continue development through the FDA IND process."
The acquired technology covers the use of RNA Interference to specifically inhibit the enzyme indolamine 2,3 deoxygenase (IDO). Tumors are known to escape the immune system by specifically activating this enzyme. In the patent and previous publication, Dr. Min and his team demonstrated that by blocking function of IDO, tumors would enter remission.
"My laboratory is looking forward to working with Bio-Matrix Scientific's Regen BioPharma towards advancing our new method of treating cancer from mice to people," stated Dr. Wei-Ping Min, Professor at the University of Western Ontario. "Having previously published(3) with Dr. Koos on our RNA interference technique, I am eager to now expand our collaboration into the area of oncology."
The cancer vaccine market is expected to grow from a 2010 value of US$12.8 billion, to US$17.4 billion by 2018. Approximately 1.5 million Americans are being diagnosed with cancer annually, and the annual overall cost of the disease is estimated to be $230 billion(4).
About Bio-Matrix Scientific Group Inc. and Regen BioPharma, Inc.:
Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) through its wholly owned subsidiary, Regen BioPharma, Inc., is a biotechnology company focused on identifying undervalued regenerative medicine patents in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/II clinical trials. To follow our development, visit us at www.regenbiopharma.com.
Disclaimer:
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
(1) http://www.jimmunol.org/content/177/8/5639.full.pdf+html
(2) http://www.fiercepharma.com/special-reports/top-10-best-selling-cancer-drugs/herceptin-166-billion
Contact:
Bio-Matrix Scientific Group, Inc. and
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
619-702-1404
www.regenbiopharma.com